Free Trial
NASDAQ:JSPR

Jasper Therapeutics Q4 2023 Earnings Report

Jasper Therapeutics logo
$4.89 +0.33 (+7.24%)
As of 04/24/2025 04:00 PM Eastern

Jasper Therapeutics EPS Results

Actual EPS
-$1.50
Consensus EPS
-$1.65
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Jasper Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Jasper Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, March 4, 2024
Conference Call Time
3:00AM ET

Upcoming Earnings

Jasper Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Monday, May 12, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Jasper Therapeutics Earnings Headlines

Jasper Therapeutics files $300M mixed securities shelf
New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
See More Jasper Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jasper Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jasper Therapeutics and other key companies, straight to your email.

About Jasper Therapeutics

Jasper Therapeutics (NASDAQ:JSPR), a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

View Jasper Therapeutics Profile

More Earnings Resources from MarketBeat